Publication: Hormonal ablation therapy for metastatic prostatic carcinoma : A review
Issued Date
1999-02-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0032913961
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.82, No.2 (1999), 192-204
Suggested Citation
Sunai Leewansangtong, Suchai Soontrapa Hormonal ablation therapy for metastatic prostatic carcinoma : A review. Journal of the Medical Association of Thailand. Vol.82, No.2 (1999), 192-204. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25687
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Hormonal ablation therapy for metastatic prostatic carcinoma : A review
Author(s)
Other Contributor(s)
Abstract
Hormonal therapy is the standard treatment for metastatic prostatic carcinoma. The conventional surgical or medical androgen ablation therapy seems to have a similar response. Despite a higher response of CAB compared to conventional castration in metastatic disease, the controversy of survival benefit remains unsolved. Immediate treatment should be given in metastatic disease particularly in patients who have minimal metastases. In patients who have progression after CAB, antiandrogens should be withdrawn. The choices of optimal therapies for prostate cancer depend not only on the survival but also the quality of life and cost effect. Thus, the critical factors for approaching prostate cancer are appropriate patient selection and stratification. Implicit with this approach should maximize benefit from maximal androgen ablation therapy for patients who are likely to profit from it. Finally, the development of experiments, clinical trials, and novel therapeutic strategies may provide better management for prostate cancer in the future.